Truist Financial Reaffirms Buy Rating for Carlsmed (NASDAQ:CARL)

Carlsmed (NASDAQ:CARL)‘s stock had its “buy” rating reaffirmed by equities researchers at Truist Financial in a research note issued to investors on Friday,Benzinga reports. They presently have a $20.00 price objective on the stock, up from their previous price objective of $18.00. Truist Financial’s target price would suggest a potential upside of 47.49% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Weiss Ratings initiated coverage on Carlsmed in a research note on Thursday, October 16th. They set a “sell (e)” rating on the stock. BTIG Research upped their target price on shares of Carlsmed from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Carlsmed has an average rating of “Hold” and an average target price of $22.00.

Carlsmed Trading Up 14.0%

Shares of CARL stock traded up $1.67 during trading hours on Friday, reaching $13.56. 83,234 shares of the company were exchanged, compared to its average volume of 133,518. Carlsmed has a fifty-two week low of $11.76 and a fifty-two week high of $16.20. The business has a fifty day moving average price of $13.59.

Carlsmed (NASDAQ:CARL) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CARL. JPMorgan Chase & Co. bought a new stake in Carlsmed in the third quarter valued at approximately $37,000. Rhumbline Advisers acquired a new position in shares of Carlsmed in the 3rd quarter valued at $79,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Carlsmed in the 3rd quarter valued at $335,000. Kornitzer Capital Management Inc. KS bought a new stake in shares of Carlsmed in the 3rd quarter valued at $736,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in Carlsmed during the 3rd quarter worth $2,026,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).